41 results about "Vascular permeability" patented technology

The invention provides a tissue microvessel analysis method and system for assisting drug design based on artificial intelligence. The method comprises the steps that two channel images of a blood vessel marking channel and a nano probe channel are collected; carrying out preprocessing, registration and feature fusion on the two channel images to obtain a fusion feature tensor for simultaneously coding a blood vessel-nanoparticle space coupling relationship; extracting multi-scale structure information based on the fusion feature tensor to obtain an enhanced feature tensor; constructing double models based on a U-Net + + architecture, and combining the double models with an enhanced feature tensor to obtain a blood vessel mask, a nanoprobe mask and a preprocessed probe intensity graph; and obtaining a permeability index based on the blood vessel mask, the nano probe mask and the preprocessed probe intensity graph, and obtaining a blood vessel typing and drug recommendation design strategy by adopting a clustering and random forest regression algorithm. According to the method, the quantitative analysis precision and efficiency of the vascular permeability are remarkably improved, intelligent linkage of image analysis and a nano-drug design strategy is realized for the first time, and the method has good application potential.

The invention discloses application of SAA1 as a target spot in preparation of a medicine for preventing and treating kidney diseases, and belongs to the field of gene functions, application and biological medicine. In-vivo and in-vitro experiments prove that in an ischemia / reperfusion or ureteral obstruction induced mouse kidney disease model, the knockout of the SAA1 gene can relieve renal interstitial vascular endothelial cell injury, recover a renal capillary network, improve vascular permeability, reduce collagen deposition, inhibit renal fibrosis and effectively delay the progress of kidney diseases; furthermore, by adopting the SAA1 recombinant protein vaccine to immunize mice, the organism can be induced to generate a protective neutralizing antibody, and the SAA1 recombinant protein vaccine has a remarkable protective effect on kidney diseases induced by ischemia / reperfusion and ureteral obstruction. Therefore, the SAA1 is an intervention target for preventing and treating the kidney diseases, the SAA1 recombinant protein vaccine is an effective means for preventing and treating the kidney diseases, and active immunization by adopting the vaccine is an effective strategy for preventing and treating the kidney diseases.

The present invention relates to an antibody trans-binding to a TEK receptor tyrosine kinase 2 (Tie2) of different cells, and a use thereof, and, more specifically, to: an antibody and use thereof, the antibody trans-binding to Tie2 of different cells so as to improve integrity between endothelial cells, perivascular cells, or endothelial cells and perivascular cells, thereby exhibiting preventive, ameliorative, or therapeutic effects on diseases associated with angiogenesis and increased vascular permeability, or diseases associated with decreased normal angiogenesis. The antibody trans-binding to an extracellular domain of the Tie2 protein, of the present invention, has excellent in vivo vascular protective activity and angiogenesis inhibitory activity, and the cluster of the antibody exhibits the activity of promoting angiogenesis, and thus can be very effectively used in the development of therapeutic agents for preventing, alleviating, or treating diseases associated with angiogenesis, increased vascular permeability, or decreased normal angiogenesis.

The application discloses a kind of hardness correlation liver cancer lung premetastatic niche mouse model construction method, it includes the following steps: (1) in vitro enrichment respectively on the low hardness substrate of hardness 6kPa and the high hardness substrate of hardness 16kPa, the condition culture supernatant of mouse liver cancer cell Hepa1-6 that is cultured and grows, respectively named mL-CM and mH-CM;(2) mL-CM and mH-CM are respectively injected into two groups of mice using tail vein injection mode, every 1 day injection 1 time, until the 26th day, during continuous monitoring the recruitment of BMDCs in fresh lung tissue, while with the induction endpoint, i.e. 26th day premetastatic niche mark feature detection includes lung tissue matrix remodeling, immunosuppression, angiogenesis, vascular permeability and inflammation etc..The method has the advantages of short modeling cycle, easy operation, controllable induction condition, can comprehensively and accurately evaluate the common characteristics of liver cancer lung premetastatic niche formation etc..

This invention provides a high-voltage pulse ablation system integrating energy transmission and real-time temperature monitoring. It includes a catheter with several electrodes, each equipped with a temperature sensing unit. A temperature monitoring unit corresponds one-to-one with each temperature sensing unit, and their ends are electrically connected via a first wiring harness and a second wiring harness. The high-voltage pulse signal generated by the main unit's pulse module is transmitted to the corresponding electrode via the first or second wiring harness of the temperature monitoring unit corresponding to that electrode, and is also transmitted back to the pulse module via the first or second wiring harness of the corresponding temperature monitoring unit of any other electrode. The temperature monitoring unit synchronously couples and filters out common-mode interference generated by the high-voltage pulse signal using the first and second wiring harnesses, and performs temperature measurement based on the differential signal obtained from the temperature sensing unit via the first and second wiring harnesses. This invention significantly reduces the catheter's outer diameter and enhances its flexibility and vascular permeability.

To provide a method for identifying a therapy recommendation for a subject exhibiting dysregulated host response.SOLUTION: A classification of the subject of subtype A, subtype B, or subtype C is obtained. The therapy recommendation for the subject is identified based at least in part on the classification. Responsive to the classification of the subject comprising the subtype A, the therapy recommendation can be no immunosuppressive therapy. Responsive to the classification of the subject comprising the subtype B, the therapy recommendation can be no therapy recommendation, immune stimulation therapy, suppression of immune regulation therapy, blocking of immune suppression therapy, blocking of complement activity therapy, and / or anti-inflammatory therapy. Responsive to the classification of the subject comprising the subtype C, the therapy recommendation can be no therapy recommendation, immune stimulation therapy, suppression of immune regulation therapy, blocking of immune suppression therapy, modulators of coagulation therapy, and / or modulators of vascular permeability therapy.SELECTED DRAWING: Figure 1A

The present invention relates to a composition for preventing or treating diabetic retinopathy, comprising a peptide having an excellent effect of inhibiting the generation of neovascularization in the retina, the loss of perivascular cells, and the expansion of blood vessels. The present invention can be effectively used in the prevention or treatment of retinopathy by inhibiting increase in vascular permeability, inflammation, and the occurrence of neovascularization.

The invention provides a traditional Chinese medicine composition, a knee strengthening ointment and a preparation method thereof. The traditional Chinese medicine composition comprises the following components in parts by weight: 8-12 parts of golden cypress, 7-15 parts of scutellaria baicalensis, 6-10 parts of coptis chinensis, 8-13 parts of rheum officinale, 5-15 parts of herba lycopi, 18-23 parts of lycopodium clavatum and 15-25 parts of obscured homalomena rhizome. The formula of the traditional Chinese medicine composition is based on the theory of traditional Chinese medicine, aims at the core pathogenesis of damp-heat blockage type knee joint edema, achieves the comprehensive treatment effects of clearing damp-heat, activating collaterals and relieving swelling and pain through the synergistic effect of multiple medicinal materials, and effectively solves the problem that three major pathological links of inflammation, vascular permeability and matrix degradation are difficult to regulate and control at the same time through an existing treatment means.

The present invention relates to a drug screening device and a drug screening method for inhibiting the vascular permeability of cancer cells. A drug screening device for inhibiting the vascular permeability of cancer cells is a microfluidic chip having a two-layer structure, including a cancer tissue region and a blood vessel region. The cancer tissue region is provided with a cancer tissue region entrance and a cancer tissue region inlet, and the blood vessel region is provided with a blood vessel region entrance and a blood vessel region inlet. A blood vessel wall model is provided between the cancer tissue region and the blood vessel region. The blood vessel wall model includes a row of flat elliptical cylinders. The elliptical cylinders are fixed to the cancer tissue regions and blood vessel regions on both sides, and the space between two adjacent elliptical cylinders is a slit. Beneficial effect: Compared with the prior art, the present invention can detect the vascular permeability of cancer cells by counting the number of cancer cells that penetrate a narrow space.

The present invention provides a recombinant type IV collagen composition for repairing basement membrane and soothing and reducing redness. The inventors found that the recombinant type IV collagen described in the specification of this patent inhibits the phosphorylation of VE-cadherin protein by mediating the PKCα / PYK2 / Src signaling pathway, protects the tight junctions between endothelial cells, prevents the leakage of blood components, and reduces vascular permeability; it can also improve the dissociation of the VE-cadherin complex caused by oxidative stress and maintain the homeostasis of the endothelial barrier; therefore, it has good effects of repairing the basement membrane barrier and soothing and reducing redness. The inventors also first discovered that the repair peptide (GAAGLPGPK) has the effects of repairing the basement membrane barrier, soothing and reducing redness, and the combination of a certain proportion of the recombinant type IV collagen and the repair peptide shows synergistic effects in repairing the basement barrier and soothing and reducing redness.

3-[(3S,4R)-3-Methyl-6-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile suppresses an increase of the retinal vascular permeability induced by VEGF, it can be used as an active ingredient of a therapeutic or preventive agent for various eye diseases involving VEGF, such as age-related macular degeneration, diabetic retinopathy, macular edema, neovascular maculopathy, retinal vein occlusion and neovascular glaucoma.

Provided are anti-syndecan-2 antibodies or antigen binding fragments thereof, as well as compositions comprising said antibody or antigen binding fragment thereof and methods useful for treating diseases associated with syndecan-2 mediated vascular permeability.

The present invention provides the use of NAMPT inhibitors in the manufacture of medicaments for preventing and / or treating pigmented villonodular synovitis (PVNS), and belongs to the field of medicine. In the present invention, based on the PVNS-PDX mouse model, it is found that NAMPT inhibitor FK866 exhibits significant therapeutic effects on PVNS, such as improving clinical symptoms related to the disease and inhibiting the proliferation of PVNS grafts. It is discovered that FK866 can target the NAMPT-ITGA5-JUND signaling axis, alleviate endothelial cell damage and vascular permeability, reduce synovial inflammation, decrease the volume of synovial tumor grafts, mitigate hemorrhagic lesions of PVNS, and hinder tumor progression. Therefore, NAMPT inhibitors have broad application prospects in the manufacture of medicaments for preventing and / or treating PVNS.

The invention provides a compound medicine for treating macular edema after cataract phacoemulsification and a preparation method of the compound medicine, and relates to the field of medicines. The compound medicine is prepared from the following raw materials in parts by weight: 18 to 23 parts of herba hedyotidis diffusae, 18 to 23 parts of rhizoma alismatis, 13 to 17 parts of herba artemisiae scopariae, 13 to 17 parts of rhizoma smilacis glabrae, 13 to 17 parts of semen plantaginis, 8 to 12 parts of rhizoma atractylodis, 8 to 12 parts of fructus gardeniae, 10 to 15 parts of white hyacinth bean, 10 to 15 parts of fructus rosae laevigatae, 8 to 12 parts of semen euryales The compound medicine disclosed by the invention is used for treating the macular edema after the cataract phacoemulsification, all the medicines are coordinated and synergistic, the effects of promoting urination and attacking evil, strengthening the spleen and consolidating the foundation, eliminating evil and calming the body resistance are achieved, microcirculation is improved, expression of peripheral blood VEGF (vascular endothelial growth factor) is reduced, vascular permeability is effectively promoted, retina recovery is promoted, and the like. The traditional Chinese medicine composition has a good clinical effect on treating macular edema after cataract ultrasonic emulsification, and has no side effect.

The invention provides an application of USP7 (ubiquitin-specific protease 7) as a target spot in preparation of drugs for treating vascular abnormal leakage diseases, and relates to the technical field of biomedicine, USP7 (ubiquitin-specific protease 7) as a deubiquitination enzyme not only regulates tumor, nerve and immune related diseases, but also is closely related to vascular endothelial cell functions. In the vascular homeostasis, the USP7 can maintain the integrity of a vascular barrier and inhibit pathological leakage by stabilizing endothelial connexin such as VE-cadherin and beta-catenin; under the inflammation or hypoxia condition, through deubiquitination of HIF-1alpha or NF-kappa B pathway components (such as I kappa B alpha), vascular endothelial cell activation can be promoted, VEGF signal-driven abnormal angiogenesis or release of inflammatory factors can be aggravated, and diabetic retinopathy, tumor vascular hyperplasia and sepsis-related vascular leakage can be participated. According to the application, verification experiments prove that USP7 has a certain protection effect on vascular permeability, and a treatment strategy is provided for vascular abnormal leakage diseases clinically.

The disclosure provides a method, a system, an apparatus, and a computer program product for determining IFP, IFV, and fluid flow inside tumors. In one example, a method for estimating tumor parameters is disclosed. This method includes: (1) receiving image data from a tumor, (2) obtaining strain data of the tumor from the image data, and (3) determining a tumor parameter, such as IFP and IFV, employing the strain data and an analytical model. Additional tumor parameters can be determined employing the strain data and other analytical models. The additional tumor parameters include compression-induced fluid pressure, velocity and flow inside the tumor, parameter a employing the fluid pressure, the ratio between vascular permeability and interstitial permeability, and the ratio of peak IFP and effective vascular pressure. Each of these parameters can be employed for analyzing, monitoring, treating, testing, etc., tumors or the effects of drugs on the tumors.

Ischemic heart disease is a leading cause of death and reduced quality of life worldwide. Although revascularization strategies significantly reduce mortality after acute myocardial infarction (MI), many patients with MI develop chronic heart failure over time. We previously reported that human recombinant ANGPTL4 counteracts ischemia-induced vascular endothelial growth factor signaling and disruption of endothelial cell-cell adhesion, thereby inhibiting vascular permeability. We were able to demonstrate that ANGPTL4 administration before MI resulted in protection of the coronary capillary network, no-reflow syndrome, and reduced infarct size in mice. We also demonstrated that the therapeutic effects observed with ANGPTL4 under ischemic conditions were caused by the FLD fragment, not the CCD fragment (WO 2016 / 110498). To further examine the therapeutic potential of the FLD fragment of ANGPTL4 at the onset of reperfusion, we herein used a porcine model, a clinically relevant model of acute myocardial infarction that can be easily and safely translated into patient treatment. We demonstrated that local (antegrade) delivery of the FLD ANGPTL4 to infarcted porcine hearts can efficiently target the lesion site in a clinically relevant manner. A single administration of the FLD of ANGPTL4 improved cardiac function, infarct size, fibrosis, and adverse remodeling parameters 28 days after MI. Short-term MI experiments, coupled with complementary mouse studies, demonstrated myocardial protection. Thus, a single administration of the FLD of ANGPTL4 can reduce ischemia-reperfusion injury and protect against adverse postischemic cardiac remodeling and subsequent ischemic heart failure.

The invention relates to the field of biological medicine, and particularly provides application of a membrane protein CMTM3 as a drug target for treating inflammatory bowel disease and related colorectal cancer. The invention discovers and verifies that deletion of Cmtm3 can protect mice from AOM / DSS induced colorectal cancer (CAC) for the first time. A further research result proves that the endothelial cell-derived CMTM3 promotes the development of enteritis. The Cmtm3 gene knockout and the imatinimex can regulate the vascular permeability in a targeted manner and have a considerable curative effect. The application also discloses that the CMTM3 promotes vascular permeability to aggravate enteritis by stabilizing CLTC and increasing gridding protein mediated endocytosis of VE-cadherin in endothelial cells, thereby promoting the development of inflammation-related colon cancer, which indicates that the CMTM3 can be used as a potential therapeutic target for enteritis and colon cancer (CAC).

The invention discloses a reagent composition for constructing an acute inflammation model and a construction method. In the invention, local slow release of TNF-alpha is realized through the temperature-sensitive hydrogel, the limitation of traditional systemic administration is broken through, the gradient diffusion characteristic of inflammatory factors in a focus area is restored, and model distortion caused by excessive activation of systemic immune response is avoided. The stepped delivery of the lipopolysaccharide, the prostaglandin E2 analogue and the IL-1beta histamine aerosol effectively covers key pathological links such as vascular permeability change, neutrophil infiltration, oxidative stress and the like through multi-channel synergistic amplification of an inflammation cascade effect. Dynamic balance maintenance of the active oxygen scavenger significantly improves the stability of the model, ensures that the inflammation process is controllable and reversible, provides a reliable window period for drug testing, and real-time fluorescence monitoring and end-point multi-index joint inspection form a closed-loop verification system, so that dynamic migration characteristics of inflammation can be captured, the end damage degree can be quantified, and the accuracy of drug detection is improved. And a complete data link from a process to a result is provided for mechanism research.

The invention discloses an application of TRAF7 in screening of anti-lung injury drugs. In an LPS-induced A549 cell acute lung injury model, TRAF7 gene knock-down significantly aggravates cell apoptosis and inflammatory response, which shows that inflammatory factor release is increased, and cell injury is aggravated; and TRAF7 overexpression can obviously inhibit the pathological change. The result shows that the TRAF7 has a protection effect on alveolar epithelial cells, the expression level of the TRAF7 is in negative correlation with the in-vitro lung injury degree, and it is proved that the TRAF7 has a negative regulation effect in acute lung injury. In a mouse ALI model, TRAF7 overexpression can significantly reduce the total number of cells, the total protein content and the wet / dry weight ratio of lung tissue in bronchoalveolar lavage fluid (BALF), relieve the pathological injury score of the lung and inhibit LY6Gneutrophil and CD68 macrophage infiltration. The TRAF7 can effectively relieve LPS-induced pulmonary edema, vascular permeability increase and tissue inflammation, and the anti-inflammatory and tissue protection functions of the TRAF7 in an in-vivo model are verified.

Methods and pharmaceutical compositions for treating ocular disease are disclosed, including ocular disease involving ocular vascular permeability or ocular inflammation. In various aspects and embodiments, the invention comprises administering about 1 μg to about 1 mg of collagen IV-derived biomimetic peptide or salt thereof to a patient by intraocular injection. Injections are provided at a frequency of from about monthly to about once every two years. In various embodiments, the methods and compositions provide for potent action and long duration of action, with infrequent intravitreal injections of a small volume.

The disclosure provides a method, a system, an apparatus, and a computer program product for determining IFP, IFV, and fluid flow inside tumors. In one example, a method for estimating tumor parameters is disclosed. This method includes: (1) receiving image data from a tumor, (2) obtaining strain data of the tumor from the image data, and (3) determining a tumor parameter, such as IFP and IFV, employing the strain data and an analytical model. Additional tumor parameters can be determined employing the strain data and other analytical models. The additional tumor parameters include compression-induced fluid pressure, velocity and flow inside the tumor, parameter ? employing the fluid pressure, the ratio between vascular permeability and interstitial permeability, and the ratio of peak IFP and effective vascular pressure. Each of these parameters can be employed for analyzing, monitoring, treating, testing, etc., tumors or the effects of drugs on the tumors.

This invention discloses a novel magnetic guidewire with a variable stiffness tip and its preparation method, belonging to the field of medical device technology. The magnetic guidewire includes a guidewire body, a magnetically controlled tip, and a spring coil. The guidewire body comprises a core wire and an outer layer. One end of the core wire is connected to the spring coil, and the end of the spring coil furthest from the core wire is connected to the magnetically controlled tip. The core wire and the spring coil are embedded together inside the magnetically controlled tip. The spring coil is a continuous spring with a gradually changing stiffness distribution along the axial direction, consisting of an unstretched section, a transition section, and a stretched section. The preparation method includes guidewire body pretreatment, spring coil treatment and fixation, magnetically controlled tip forming, and post-treatment. This invention solves the problems of uneven stiffness transition, easy slippage of the magnetically controlled tip, and susceptibility to puncture by the core wire in conventional magnetic guidewires. It achieves a natural and smooth stiffness transition, improves vascular permeability and connection stability, has a simple preparation process, good biocompatibility, and is suitable for vascular interventional surgery.

The invention discloses a traditional Chinese medicine composition and application thereof in low-deuterium small molecular group compound wine. The traditional Chinese medicine composition is prepared from the following components in parts by mass: 40 parts of an anti-tumor compound, 50-70 parts of rhizoma polygonati, 50-75 parts of fructus lycii, 45-65 parts of herba cistanche and 2-7 parts of fructus ziziphi jujubae, the anti-tumor compound is prepared from antrodia camphorata and ganoderma lucidum according to the mass ratio of (2-4): 1. The traditional Chinese medicine composition and the small-molecular-group low-deuterium compound wine prepared from the traditional Chinese medicine composition have the advantages that the negative influence of traditional Chinese liquor on human health is remarkably relieved, and the effects of nourishing the liver, tonifying the kidney, regulating both the liver and the kidney, regulating blood sugar and blood fat, improving vascular permeability, improving immunity and inhibiting tumors are achieved for a liquor product through the traditional Chinese medicine composition and the small-molecular-group low-deuterium compound wine prepared from the traditional Chinese medicine composition; and 2) experiments show that the traditional Chinese medicine composition provided by the invention obviously improves the inhibition rate of natural traditional Chinese medicines on liver cancer HepG2 cells.

Provided herein are molecules, compositions and methods for treating an ocular disease or disorder, comprising: administering to a subject an aqueous pharmaceutical composition, wherein the composition comprises a molecule, or a pharmaceutically acceptable salt thereof, and having reduced or no antimicrobial activity, wherein the molecule is selected from at least one of structure A, B, C, or D having the R-groups listed for each. The ocular disease or disorder is selected from the group consisting of abnormal angiogenesis, choroidal neovascularization (CNV), age-related macular degeneration (AMD), neovascular (exudative) age-related macular degeneration (nAMD), diabetic retinopathy, retinal vascular permeability, retinal edema, diabetic retinopathy, diabetic macular edema (DME), CNV associated with nAMD, sequela, associated with retinal ischemia, central retinal vein occlusion, and posterior segment neovascularization.

The invention discloses a tumor cell targeting controllable response nanometer material and a preparation method and application thereof.The controllable response nanometer material comprises a metal organic framework and a polydopamine shell wrapping the metal organic framework, and the metal organic framework is internally loaded with a photosensitizer and an anti-tumor drug; the surface of the polydopamine shell is modified with a first functional unit and a second functional unit, the first functional unit and the second functional unit contain primary amine groups, and the first functional unit and / or the second functional unit target tumor cells. The controllable response nano-material provided by the invention is used for jointly treating tumors through multiple mechanisms, is combined with a photosensitizer, a tumor drug and a photothermal effect, not only can accurately target tumor cells, but also can enhance tumor immune response, and the nano-particles also can enhance the delivery efficiency of the drug by adjusting a tumor microenvironment, so that the tumor immune response is enhanced. And the blood vessel permeability of a tumor area is improved, the limitation of a traditional treatment means is broken through, and a multi-level and multi-target comprehensive treatment strategy is formed, so that more efficient and comprehensive tumor treatment is realized.

The invention discloses a nano preparation for near-infrared two-region fluorescence imaging guided collaborative treatment of rheumatoid arthritis and a preparation method of the nano preparation, and belongs to the technical field of nano biomedical materials. The preparation method comprises the following steps: firstly, preparing Au-Pt alloy nanoclusters with near-infrared two-region fluorescence emission characteristics through a simple and efficient'one-pot method 'synthesis strategy; and then, carrying out surface modification on the alloy nanocluster by using bovine serum albumin to form the multifunctional nano preparation AuPt-coated BSA. After intravenous injection, the nano preparation AuPt-coated BSA realizes passive targeting through enhanced vascular permeation and retention effects of a lesion joint part, realizes active targeting by utilizing the ability of bovine serum albumin to be specifically recognized and taken by inflammatory cells, and is efficiently enriched at a joint inflammation part. The AuPt-coated BSA nano preparation catalyzes endogenous hydrogen peroxide to be decomposed to generate oxygen, so that local high-expression active oxygen is directly removed, the hypoxic microenvironment is effectively relieved, and collaborative treatment of rheumatoid arthritis mediated by near-infrared two-region fluorescence imaging is achieved.

The present application relates to the field of biological medicine, and specifically, the present application provides a kind of membrane protein CMTM3 as the application of drug target for treating inflammatory bowel disease and its related colorectal cancer.The present application first finds and confirms that the deletion of Cmtm3 can protect mice from AOM / DSS-induced colorectal cancer (CAC).Our further research results confirm that endothelial cell-derived CMTM3 promotes the development of intestinal inflammation.Cmtm3 gene knockout and imatinib mesylate can both target the regulation of vascular permeability and have comparable efficacy.And the present application also discloses that CMTM3 promotes intestinal inflammation by stabilizing CLTC and increasing the clathrin-mediated endocytosis of VE-cadherin in endothelial cells, thereby promoting the development of inflammation-related colon cancer, indicating that CMTM3 can be used as a potential therapeutic target for intestinal inflammation and colon cancer (CAC).

The invention belongs to the technical field of cancer treatment, and discloses an application of an sTREM2-NCL-AKT / eNOS axis in the vascular permeability of ovarian cancer and the formation of malignant ascites. The invention proves that the level of the sTREM2 is increased in ascites of an ovarian cancer patient, discloses the effect of the sTREM2 in promoting vascular permeability and driving ascites formation, and puts forward that the sTREM2 has double values of a prognosis biomarker and a potential treatment target. The discovery lays a foundation for developing accurate treatment for ovarian cancer and malignant ascites. In mechanism, the sTREM2 activates an AKT / eNOS signal channel through interaction with a cell surface nucleolin (NCL) protein, so that the integrity of an endothelial barrier is damaged. Targeting or blocking sTREM2 effectively mitigates vascular leakage and ascites production. According to the discovery, the sTREM2 is determined as a core driving factor of ascites pathogenesis, and the potential of the sTREM2 as an ovarian cancer treatment target is highlighted.

The present invention relates to a composition for preventing or treating diabetic retinopathy, comprising a peptide, wherein the peptide exhibits excellent inhibition with respect to vasodilation, loss of pericytes, and generation of neovascularity in the retina, and thus can be effectively used for preventing or treating retinopathy by inhibiting an increase in vascular permeability, inflammation, and the occurrence of neovascularity.